Aura Biosciences, Inc.
AURA
$7.00
$0.142.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.98% | -1.41% | 3.58% | 11.52% | 16.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.35% | 17.35% | 21.78% | 20.30% | 17.05% |
| Operating Income | -15.35% | -17.35% | -21.78% | -20.30% | -17.05% |
| Income Before Tax | -18.69% | -22.21% | -28.15% | -25.77% | -20.58% |
| Income Tax Expenses | 17.65% | -5.31% | -48.67% | -27.32% | -53.55% |
| Earnings from Continuing Operations | -18.69% | -22.17% | -27.94% | -25.65% | -20.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.69% | -22.17% | -27.94% | -25.65% | -20.40% |
| EBIT | -15.35% | -17.35% | -21.78% | -20.30% | -17.05% |
| EBITDA | -15.63% | -17.67% | -22.19% | -20.71% | -17.37% |
| EPS Basic | 8.29% | -2.36% | -11.54% | -9.26% | -2.01% |
| Normalized Basic EPS | 8.29% | -2.38% | -11.42% | -9.07% | -1.87% |
| EPS Diluted | 8.29% | -2.36% | -11.54% | -9.26% | -2.01% |
| Normalized Diluted EPS | 8.29% | -2.38% | -11.42% | -9.07% | -1.87% |
| Average Basic Shares Outstanding | 29.72% | 21.44% | 15.88% | 14.25% | 17.12% |
| Average Diluted Shares Outstanding | 29.72% | 21.44% | 15.88% | 14.25% | 17.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |